TSX:EPRX • CA29842P1053
Past quarterly earnings results for EUPRAXIA PHARMACEUTICALS INC (EPRX.CA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.26 | -0.22 | -18.58% | -12.93% | - | - | ||
| Q2 2025 | -0.36 | -0.25 | -41.57% | -54.51% | - | - | ||
| Q1 2025 | -0.30 | -0.24 | -23.87% | -6.36% | - | - | ||
| Q4 2024 | -0.28 | -0.16 | -80.04% | 26.32% | - | - | ||
| Q3 2024 | -0.23 | -0.27 | 12.99% | 7.20% | - | - | ||
| Q2 2024 | -0.23 | -0.24 | 2.06% | 35.28% | - | - | ||
| Q1 2024 | -0.28 | -0.35 | 18.21% | -23.04% | - | - | ||
| Q4 2023 | -0.38 | -0.24 | -55.23% | 7.32% | - | - | ||
| Q3 2023 | -0.25 | -0.33 | 23.41% | - | - | - | ||
| Q2 2023 | -0.36 | -0.37 | 1.96% | - | - | - | ||
| Q1 2023 | -0.23 | -0.37 | 37.36% | - | - | - | ||
| Q4 2022 | -0.41 | -0.44 | 6.52% | -51.85% | - | - | ||
| Q3 2022 | - | - | - | - | ||||
| Q2 2022 | - | - | - | - | ||||
| Q1 2022 | - | - | - | - | ||||
| Q4 2021 | -0.27 | -0.43 | 36.97% | - | - | - | ||
| Q3 2021 | -0.22 | - | - | - | - | |||
| Q2 2021 | -0.38 | -0.56 | 31.64% | - | - | - | ||
| Q1 2021 | -0.86 | -0.14 | -524.55% | - | - | - | ||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) last reported earnings on 11/4/2025.
EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) has beaten EPS estimates in 0 out of 4 releases.